Overview

PK/PD Study of YZJ-1139

Status:
COMPLETED
Trial end date:
2019-11-15
Target enrollment:
Participant gender:
Summary
Primary Objective To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses. Secondary Objective: To investigate the safety and tolerability of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Treatments:
Zolpidem